Back to company

Solid Therapeutics ApS: Financial statements 2024

CVR: 43007068

Solid Therapeutics ApS (CVR 43007068) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -4,213,656 and a net result of DKK -6,758,207 compared with DKK -3,483,115 the year before. Equity amounted to DKK -10,998,141. The company had 4 employees in the financial year.

Gross Profit
-4,213,656 kr.
Profit/Loss
-6,758,207 kr.
Equity
-10,998,141 kr.
Total Assets
11,003,832 kr.
Employees
4

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--4.2 mio.-6.8 mio.-11 mio.4
2023--2.7 mio.-3.5 mio.-4.2 mio.2
2022--398 t.-797 t.-757 t.1

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Solid Therapeutics ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2024

Solid Therapeutics ApS: The 2023 annual report is outJun 12, 2024

Solid Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -2,738,806, and the net result was DKK -3,483,115.

About Solid Therapeutics ApS

Solid Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of John Sørensen Haurum. The company's owners include John Sørensen Haurum, Stine Helene Falsig Petersen and Anne Mette Hyldgaard Trauelsen. In 2025, the company reported a gross profit of DKK -1,687,751 and a net result of DKK -4,355,625 compared with DKK -6,758,207 the year before. Equity amounted to DKK -15,353,766.

Other financial years